About PER - Overview

Advancing Cancer Care through Professional Education

Physicians' Education Resource (PER) is a continuing medical education company specializing in oncology and hematology. Since 1996, PER has coordinated and implemented superior educational opportunities that enable health care professionals to remain current and responsive to advances in medical care for cancer patients, from diagnosis through treatment.

PER is accredited to provide continuing education to physicians, nurses, and pharmacists through the Accreditation Council for Continuing Medical Education (ACCME), Texas Nurses Association (TNA), and Accreditation Council for Pharmacy Education (ACPE). PER is compliant with other regulatory bodies, including the American Medical Association (AMA), Office of Inspector General (OIG), Food and Drug Administration (FDA), and Pharmaceutical Research and Manufacturers (PhRMA). Our programs, which are developed in conjunction with over 1000 oncology thought leaders, universities, and health care associations worldwide, are accessed by the majority of all US oncology practitioners and are growing rapidly in Europe and Asia.

From international congresses to local community-based meetings as well as print and online case studies, major meeting highlights, literature reviews, and other publications, our interactive programs keep health care professionals up-to-date on the most recent developments in cancer care with the ultimate goal to improve patient outcomes.

PER's Organization

PER is an independent corporation within Medical Media Holdings (MMH), a holding company that provides general support services for a family of subsidiaries, each of which is separately incorporated and independently operated. PER's sister subsidiary that also produces independent educational activities is CIG Media Group.

CIG Media Group (formerly Cancer Information Group): Dedicated to publishing a series of peer-reviewed, disease-specific oncology journals that disseminate cutting edge data to the practicing clinician:

Clinical Breast Cancer (PubMed indexed, Impact Factor of 2.247)

Clinical Colorectal Cancer (PubMed indexed, Impact Factor of 2.724)

Clinical Lung Cancer (PubMed indexed, Impact Factor of 2.393)

Clinical Lymphoma, Myeloma & Leukemia (PubMed indexed, Impact Factor of 1.596)

Clinical Ovarian Cancer (Launched in 2008)

Read More information on the products and services of CIG Media Group

Online CME Updates

THERAPY ADVANCES

First-line Therapy for Colorectal Cancer

Get the latest clinical data and treatment recommendations concerning the first-line treatment of a patient with metastatic CRC.

Go to activity >>

TUMOR BIOLOGY

Triple-Negative Breast Cancer: Exploiting Tumor Biology to Improve Patient Outcomes

This satellite symposium reviews the latest advances in the biology and treatment of triple-negative breast cancer and provides practical information on optimizing patient care.

Access here >>

CLINICAL BREAST CANCER

Optimizing Treatment of Early-Stage Breast Cancer

Find out the latest therapies and treatment decision-making strategies for patients with early-stage breast cancer, including incorporation of cytotoxic and targeted agents and risk/benefit assessment.

Get the facts >>